Chronic Kidney Disease

The FDA's decision not to approve sotagliflozin as an adjunct in T1D and CKD comes less than 2 months after a negative advisory committee meeting for the application.

Matthew Weir, MD discusses how a multidisciplinary approach is reshaping CKD management, with a focus on mitigating cardiovascular events.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

Katherine Tuttle, MD, joins the podcast for a deep dive into the latest FLOW data from Kidney Week 2024.

Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.

The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.

Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.

New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.

After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.

New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.

RIVUR analysis suggests recurrent UTIs in children with VUR may lower eGFR, even without kidney scarring, especially in those with multiple febrile infections.

Kidney Compass: Navigating Clinical Trials is a multimedia podcast from HCPLive hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, aimed at exploring the latest in clinical trials and updates in nephrology.

This retrospective analysis examined the current management of early and late anemia in a representative sample of the kidney transplant population in Spain.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

Lack of retinopathy, lower hemoglobin A1c levels, preserved eGFR, microalbuminuria, and lower UPCR were linked to non-DKD.

Leveraging deceased donor kidney transplantation data, study results suggest DCD-V kidney transplantation has similar short- and long-term outcomes versus DCD-III and DBD.